How do doctors guide their patients to work effectively despite the breathing disorder or seek modifications to their job ...

Having recently scored approval for Nucala in chronic obstructive pulmonary disease (COPD), GSK has now signed a major ...

GSK and Hengrui Pharma signed a global deal for up to 12 drugs, including COPD therapy, with milestone payments totaling $12 ...

As frontline partners, PCPs coordinate work-up, referrals, and lifestyle counseling in dyspnea. Review essential steps for ...

The annual Best Hospitals report from US News & World Report compares more than 4,500 hospitals across 15 specialties and 22 ...

The two companies have entered into an agreement to develop respiratory, immunology, inflammation, and cancer therapies.

Britain's GSK and China's Jiangsu Hengrui Pharmaceuticals have agreed on a $500 million deal to develop up to a dozen new ...

Hengrui Pharma enters agreement and with GSK to develop up to 12 innovative medicines across respiratory, immunology & inflammation & oncology: Jiangsu, China Tuesday, July 29, 20 ...

The deal, which focuses first on a COPD drug GSK believes holds “best-in-class” potential, could involve a dozen medicines ...

GSK plc has entered into agreements with China-based biotechnology company Hengrui Pharma to develop up to 12 innovative ...

Elderly Patients, Inguinal Hernia, Treatment Options, Surgical Methods, Mesh, Non-Surgical Treatment Share and Cite: Mo, Q.Y. and Huang, Q.L. (2025) Research Progress on Treatment Options for Inguinal ...

Pharma giant Glaxosmithkline, which has major operations in Upper Providence and West Point, is partnering with China-based Hengrui Pharma, writes the ...